HYTERA
24.5.2021 12:24:07 CEST | Business Wire | Press release
Hytera , as a world leading provider of professional communications technologies and solutions, brings body worn cameras (BWC) to a new level with innovative hardware and software design, convergence with push-to-talk technology, and integration with control room solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005363/en/
Hytera has full series of 4G or LTE body worn cameras which can capture HD video to provide evidence for trials. More importantly, they are able to send live video back to the control center over 4G network. This helps the dispatcher know exactly what is happening, enhance real-time situational awareness and facilitate decision-making. Hytera has launched a comprehensive solution including the body worn camera, integrated device station and digital evidence management platform.
Designed for the field with evidence management in mind, the VM780 takes RVM Bodycams to the next level with the most advanced range of features available, including a 2.8” touch display, 3G/ 4G & Wi-Fi for real time transmission anywhere, GPS built-in and Push-to-talk over cellular (PoC) application compatibility. The device features a 216° rotatable camera and powerful 3-watt speaker to deliver loud and clear audio during the call, even in highly noisy environments. It also supports NFC and Bluetooth connectivity, AES256 advanced encryption technology, and simple charging and programming via the micro-USB interface.
The VM580D is suitable for both mission critical and commercial users. It’s slim (only 20mm thick), lightweight and easy to operate with one hand for photo taking, audio and video recording. It can share real-time GPS location information over LTE, 3G, and Wi-Fi networks. The device also serves as a PoC radio, which can be used for evidence collection simultaneously with a PoC platform such as Hytera HyTalk.
Hytera also provides various related software and hardware including storage, evidence collection, evidence classification, and dispatch platform, etc. Hytera is one of the few companies which can provide E2E body worn cameras solution to customers.
It's known to all that it is not uncommon for the officers to face the confrontations or dispute from the public during onsite law enforcement. Public safety and governmental institutions have increasingly advocated or legislated the use of BWC for promoting law enforcement transparency, deterring the violence and increasing trial efficiency. For example, a Dubai ruler issued a resolution to authorize its police to use security cameras in public areas to fulfill its duties including handling traffic violations and ensuring effective security. Hytera BWC Solution has been adopted by government and industry customers including the Shanghai Police and Macau Police to restore the truth of what happened with the first-person recording, voice and video, and bring better transparency and accountability to help improve law enforcement legitimacy.
Learn more at http://www.hytera.ae .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005363/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom